Search
Autolus Therapeutics PLC
AUTLAdd to Watchlist
1.630USD
+0.040+2.52%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
433.83MMarket Cap
LossP/E TTM
More Details of Autolus Therapeutics PLC Company
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Autolus Therapeutics PLC Info
Ticker SymbolAUTL
Company nameAutolus Therapeutics PLC
IPO dateJun 22, 2018
CEOItin (Christian Martin)
Number of employees647
Security typeDepository Receipt
Fiscal year-endJun 22
AddressThe Mediaworks
CityLONDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeW12 7FP
Phone442038296230
Websitehttps://www.autolus.com/
Ticker SymbolAUTL
IPO dateJun 22, 2018
CEOItin (Christian Martin)
Company Executives of Autolus Therapeutics PLC
Name
Name/Position
Position
Shareholding
Change
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. Brent Rice
Mr. Brent Rice
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
9.40K
--
Dr. Christian Martin Itin, Ph.D.
Dr. Christian Martin Itin, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Martin Pule
Mr. Martin Pule
Founder, Senior Vice President, Chief Scientific Officer
Founder, Senior Vice President, Chief Scientific Officer
--
--
Mr. Christopher Vann
Mr. Christopher Vann
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
Mr. David Brochu
Mr. David Brochu
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
--
--
Mr. John Edward Berriman
Mr. John Edward Berriman
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Linda C. Bain
Ms. Linda C. Bain
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William D. (Bill) Young, Ph.D.
Mr. William D. (Bill) Young, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Elisabeth (Lis) Leiderman, M.D.
Dr. Elisabeth (Lis) Leiderman, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. Brent Rice
Mr. Brent Rice
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
9.40K
--
Dr. Christian Martin Itin, Ph.D.
Dr. Christian Martin Itin, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Martin Pule
Mr. Martin Pule
Founder, Senior Vice President, Chief Scientific Officer
Founder, Senior Vice President, Chief Scientific Officer
--
--
Mr. Christopher Vann
Mr. Christopher Vann
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
Mr. David Brochu
Mr. David Brochu
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
1.02M
95.33%
Europe
50.00K
4.67%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Apr 20
Updated: Mon, Apr 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BioNTech SE
12.52%
Syncona Investment Management Limited
11.55%
MAK Capital One, LLC
11.27%
Clarus Ventures, LLC
7.70%
Blackstone Inc.
7.70%
Other
49.26%
Shareholders
Shareholders
Proportion
BioNTech SE
12.52%
Syncona Investment Management Limited
11.55%
MAK Capital One, LLC
11.27%
Clarus Ventures, LLC
7.70%
Blackstone Inc.
7.70%
Other
49.26%
Shareholder Types
Shareholders
Proportion
Investment Advisor
23.99%
Hedge Fund
21.10%
Corporation
12.52%
Private Equity
9.43%
Venture Capital
8.01%
Investment Advisor/Hedge Fund
7.75%
Sovereign Wealth Fund
5.64%
Holding Company
5.55%
Research Firm
1.64%
Other
4.36%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
239
209.95M
78.88%
-50.13M
2025Q4
230
194.47M
90.55%
+128.60K
2025Q3
237
202.34M
94.14%
-20.86M
2025Q2
235
223.88M
91.00%
-2.80M
2025Q1
228
230.12M
90.84%
-11.63M
2024Q4
235
229.60M
92.37%
-10.27M
2024Q3
225
234.01M
89.22%
+30.38M
2024Q2
227
202.70M
79.95%
+2.45M
2024Q1
217
200.05M
58.18%
+45.35M
2023Q4
191
140.21M
76.10%
+4.14M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Syncona Investment Management Limited
30.73M
11.55%
+30.73M
--
Sep 30, 2024
MAK Capital One, LLC
30.01M
11.27%
+3.99M
+15.33%
Dec 31, 2025
Clarus Ventures, LLC
20.49M
7.7%
--
--
Sep 30, 2025
Blackstone Inc.
20.49M
7.7%
+20.49M
--
Dec 31, 2025
Armistice Capital LLC
17.50M
6.58%
+1.90M
+12.18%
Dec 31, 2025
Syncona Portfolio Ltd
16.64M
6.25%
--
--
Dec 31, 2025
Qatar Investment Authority
15.00M
5.64%
--
--
Mar 01, 2025
PPF Group N.V.
14.78M
5.55%
+170.00K
+1.16%
Oct 24, 2024
Polygon Management Ltd.
9.50M
3.57%
--
--
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.56%
Virtus LifeSci Biotech Clinical Trials ETF
0.49%
ALPS Medical Breakthroughs ETF
0.17%
iShares Health Innovation Active ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.02%
SPDR S&P International Small Cap ETF
0.01%
Tema Oncology ETF
0%
Fidelity Fundamental Small-Mid Cap ETF
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.56%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.49%
ALPS Medical Breakthroughs ETF
Proportion0.17%
iShares Health Innovation Active ETF
Proportion0.07%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
iShares Biotechnology ETF
Proportion0.02%
SPDR S&P International Small Cap ETF
Proportion0.01%
Tema Oncology ETF
Proportion0%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
